News | May 13, 2024
Briefs: Lupin and Aurobindo Pharma
Lupin updates on shipment of Mirabegron ER Tablets
Lupin updates on shipment of Mirabegron ER Tablets
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company is committed to address this observation comprehensively within stipulated time
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
The USFDA has issued 5 observations pursuant to the completion of audit
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Subscribe To Our Newsletter & Stay Updated
